By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS


Industry
Pharmaceutical






Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma 11/19/2014 12:28:07 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Stifel 2014 Healthcare Conference 11/11/2014 12:33:03 PM
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014 10:51:41 AM
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014 6:10:45 AM
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302 11/11/2014 6:09:55 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma To Be Presented At The 2014 American Society of Hematology Annual Meeting 11/7/2014 12:13:02 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces New Phase 1/2 Data On TH-302 In Glioblastoma To Be Presented At The 2014 SNO Annual Meeting 11/4/2014 1:05:46 PM
Threshold Pharmaceuticals, Inc. (THLD) Reports Third Quarter 2014 Financial And Operational Results 11/4/2014 1:00:06 PM
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Completes Target Enrollment In The TH-302 Phase 3 MAESTRO Study In Patients With Locally Advanced Or Metastatic Pancreatic Adenocarcinoma 11/4/2014 11:04:17 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Its Phase 3 Trial Of TH-302 In Patients With Advanced Soft Tissue Sarcoma Will Continue As Planned Following Protocol-Specified Interim Analysis 9/22/2014 11:10:42 AM
12345678910...
//-->